Skip to Main

32nd Annual Healthcare Conference

  • March 15-17, 2022
  • Virtual

This conference will provide investors a broad spectrum of public and private healthcare companies spanning all major sectors of the healthcare industry: bio & specialty pharmaceuticals; biotechnology; medical devices; life science tools and diagnostics; healthcare information technology and distribution; and healthcare providers and servicers.

The Healthcare ecosystem has never been as complex nor as full of opportunities. Therapies and treatments are evolving more rapidly than investors have been able to keep up with. The 32nd Annual Oppenheimer Healthcare Conference will showcase nearly 300 companies that will likely shape the industry for the next decade to come.

Monday, March 14, 2022Healthcare Conference Kick-Off Call Series

In conjunction with Oppenheimer’s 32nd Annual Healthcare Conference

We are pleased to announce a series of calls on Monday, March 14th as a kick-off event in advance of Oppenheimer’s 32nd Annual Healthcare Conference. The call series will feature innovative thought leaders, biotech pioneers, and renowned therapeutics experts discussing key topics. Oppenheimer analysts will host a variety of hour long expert calls and fireside chat discussions to provide insight around key issues impacting the healthcare sector.

Replays will be available after the conference.

Schedule of Calls

Monday, March 14th, 2022

Oppenheimer Hosts

Kevin DeGeeter
Managing Director & Senior Research Analyst
Biotechnology & Diagnostics
Hartaj Singh
Managing Director & Senior Research Analyst
Justin Kim
Senior Research Analyst

Keynote Speakers

Joseph Mercer
Managing Director; Managed Care and Healthcare Services Senior Analyst

Mr. Mercer leads Marwood’s healthcare services and managed care practices. Prior to joining the Marwood Group, he served as a Program Analyst at the Center for Consumer Information and Insurance Oversight (CCIIO) division at CMS. From his tenure at CCIIO, Mr. Mercer brings with him substantial expertise covering government health insurance programs with a focus on ACA exchange and Medicare Advantage policy issues and catalysts. As a Program Analyst at CCIIO, some of his core responsibilities included tracking Federal and State legislative and regulatory changes, translating statutory and regulatory requirements into policy guidance, analyzing provisions of the Affordable Care Act for Federal and State regulators (as well as health insurers), serving as a health insurance issuer rating subject matter expert, and collaborating with other CCIIO groups and contractors with a primary focus on working with the Federally Facilitated Marketplace development and policy teams. Mr. Mercer holds a JD from Washington & Lee University School of Law and a BA in Economics from the College of William and Mary.

Mark Galay
Vice President; Congressional Health Policy Senior Analyst

Mr. Galay focuses on legislative affairs, maintaining Congressional and industry relations, and healthcare policy analysis for Marwood Group. Previously, he served as the Legislative Assistant for a senior member of the House Ways & Means Committee. In his work, he developed the Congressman’s legislative health care agenda, introducing several pieces of legislation, some of which signed into law. He advised the Congressmen on key health policy initiatives such as the 21st Century Cures Act, the repeal & replace debate, and the SUPPORT for Patients and Communities Act. Mr. Galay studied Biology and Chemistry at Cleveland State University.

Steve Williams, PhD
Director; Pharma/Biotech and Life Sciences Senior Analyst

Dr. Williams leads Marwood’s life sciences team, which includes coverage of pharmaceuticals, biotechnology, clinical laboratories, PBMs, and medical devices. This includes focusing on analyzing regulatory issues related to the Food and Drug Administration (FDA) and other federal agencies responsible for regulating medical products. Prior to joining the Marwood Group, Dr. Williams was an investment banker focused on pharmaceutical and biotechnology companies, working with privately held and publicly traded companies to raise growth capital and develop business development strategies. Prior to that, he was an equity analyst covering the pharmaceutical and biotech industries, covering over a dozen U.S. and European companies. Before working in the financial sector, Dr. Williams was a biomedical researcher and held faculty positions at Vanderbilt University and Baylor College of Medicine. He holds a PhD in pharmacology from London University and an MBA from George Washington University.

Dr. Brett Giroir
Current CEO of Altesa BioSciences, Inc. and Former Assistant Secretary for Health and Acting FDA Commissioner and Admiral, US Public Health Service

Dr. Brett Giroir is a physician-scientist and innovator whose career has been dedicated to improving public health and medical science. Formerly, he served as the 16th Assistant Secretary for Health in the U.S. Department of Health and Human Services, Acting FDA Commissioner, and Admiral in the US Public Health Service Commissioned Corps. He also served as the US Representative to the Executive Board of the World Health Organization within the Department of State. Notably, Dr. Giroir was on the front lines of the COVID-19 response as a member of the White House Coronavirus Task Force and the national lead for testing and diagnostics (“Testing Czar”).

Dr. Matt McCarthy
Associate Professor of Medicine, Weill Cornell Medicine

Matt McCarthy, MD is an associate professor of medicine at Weill Cornell Medicine, a staff physician at NewYork-Presbyterian Hospital, and the author of three bestselling books, including the international bestseller, Superbugs: The Race to Stop an Epidemic. Dr. McCarthy was the first COVID-19 attending hospitalist at NewYork-Presbyterian Hospital, where he was responsible for determining best practices and research protocols, and he has now treated over 1500 COVID-19 patients. He has served as a pandemic advisor to the United States Army, New York City public schools, the American Museum of Natural History, both Republican and Democrat congressmen, and a variety of international corporations. He appears regularly on Fox Business.

Participating Companies

Click here Participating Companies

Notable Transactions

Quotation from Aenean Pretium

While the Street is justifiably concerned about the recent biotech drawdown, we are excited to host a plethora of innovative companies with focused management teams in mid-March. It is our belief that this is the time to do the work and find healthcare-changing innovation.

Hartaj Singh, Senior Equity Analyst

Let’s Talk FutureTM Podcast

Our latest episodes provide timely and relevant discussions with our thought leaders in the healthcare industry.